This is a news story, published by ScienceDaily, that relates primarily to myelin news.
For more myelin news, you can click here:
more myelin newsFor more disease research news, you can click here:
more disease research newsFor more news from ScienceDaily, you can click here:
more news from ScienceDailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
certain MS therapies. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest primary progressive multiple sclerosis news, MS therapies news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
MS medicationsScienceDaily
•
79% Informative
Study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white blood cells called B-cells.
With MS , the body's immune system attacks myelin , the fatty, white substance that insulates and protects the nerves.
VR Score
90
Informative language
95
Neutral language
76
Article tone
formal
Language
English
Language complexity
59
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links